SELLAS Life Sciences Group (SLS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- —
- Estimate
- -$0.04
- Surprise
- —
- Score today
- 4.8/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- 10 Health Care Stocks With Whale Alerts In Today’s Session — benzinga, 2026-08-12
- SELLAS Life Sciences Gr Q2 EPS $(0.05) Misses $(0.04) Estimate — benzinga, 2026-08-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates SLS Sell at 4.8/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-11.
What argues against it
- Quality below floor (1.6 < 4.0)
- Value-trap signals (3/5): Margin compression (op margin -182.6%), High leverage (D/E 13.7), Negative free cash flow
- Momentum score 3.7/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $13.99
- Price target
- $27.62
- Stop
- $12.98
- Upside to target
- +97.4%
- Reward-to-risk
- 6.5:1
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
SLS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.77B
- P/E (fwd)
- -137.0
- 52-week range
- $1.39–$15.88
- Off 52-week high
- 11.9%
- RSI (14)
- 55
- Volume vs avg
- 0.20×
- Score today
- 4.8/10